icsm-tt-monotherapy-mild-ed

name	icsm-tt-monotherapy-mild-ed
description	Reserve testosterone monotherapy for men with mild erectile dysfunction and an absolute demonstration of hypogonadism; otherwise combine testosterone therapy with a PDE5 inhibitor. Triggered when a clinician managing erectile dysfunction asks whether testosterone alone is sufficient or a PDE5 inhibitor should be added.

Reserve testosterone monotherapy for mild erectile dysfunction with proven hypogonadism

STEP 1 — Gather Information

• Confirm erectile dysfunction and assess severity (mild vs moderate/severe) using IIEF-5 or clinical judgment.
• Document symptoms suggestive of hypogonadism (low libido, decreased morning erections, fatigue).
• Obtain two morning total testosterone (tT) measurements (fasting, 07:00–11:00 h) using a reliable assay; absolute demonstration of hypogonadism = tT <12 nmol/L on both occasions.
• Note any prior use of PDE5 inhibitors and response.

STEP 2 — Rule In / Rule Out

Is the erectile dysfunction mild?

• No → Testosterone monotherapy not appropriate; proceed to combination therapy or PDE5 inhibitor alone based on hypogonadism status.
• Yes → Continue to assess hypogonadism.

STEP 3 — Classify or Stratify

Is there an absolute demonstration of hypogonadism (tT <12 nmol/L on two morning samples)?

• Yes → Candidate for testosterone monotherapy.
• No → Testosterone monotherapy not indicated; consider combining testosterone therapy with a PDE5 inhibitor.

STEP 4 — Decide

• If mild ED and absolute hypogonadism → Initiate testosterone monotherapy (e.g., transdermal gel targeting mid-normal tT).
• Otherwise → Prescribe testosterone therapy combined with a PDE5 inhibitor (or PDE5 inhibitor alone if eugonadal) and reassess erectile function in 3 months.

Clinical Guardrails / Mimics / Pitfalls

• Do not use testosterone monotherapy in men without two‑step approach: never start monotherapy without confirming low tT on two separate occasions.
• Avoid monotherapy in moderate or severe ED; efficacy is limited and combination is preferred.
• Monitor hematocrit, PSA, and symptoms; withdraw if hematocrit >54% or adverse events occur.
• Do not rely on monotherapy to treat depression, obesity, or metabolic disease alone.

Concrete Clinical Example

A 58‑year‑old man reports mild erections (IIEF‑5 16) and low libido. Morning tT is 10 nmol/L on two separate visits. He asks if testosterone alone will help. Since ED is mild and hypogonadism is proven, start testosterone gel 5 mg daily. At 3‑month follow‑up, IIEF‑5 improves to 20; if further improvement desired, add sildenafil 50 mg PRN.

Source: International Consultation on Sexual Medicine (ICSM) 2024, Box2 Recommendation 8, 2025, https://doi.org/10.1093/sxmrev/qeaf036